Tirzepatide online access for Kearney, Nebraska
Company statements checked between September 10, 2026 and September 23, 2026: 2 covered companies — Gentle Health and GoodRx Care — advertise online access to Tirzepatide for patients in Nebraska, including Kearney. Confirm eligibility and total charges with the provider.
Browse online Tirzepatide programs advertised for patients in Kearney, Nebraska, with state-level access evidence.
Inside Telehealth Editorial · Updated
At a glance
| Company | On this page | Lowest listed monthly figure | Checked | Official site |
|---|---|---|---|---|
| Gentle Health | Compounded injectable tirzepatide | $169/mo advertised monthly bundle, Compounded injectable tirzepatide | Official site ↗ | |
| GoodRx Care | Zepbound KwikPen | $338/mo partial monthly subtotal, Zepbound KwikPen | Official site ↗ |
Health context in Kearney
Tirzepatide programs are marketed for weight management and, for some products, type 2 diabetes. These Kearney figures give local context only. Among the 5 Nebraska cities in this research set, Kearney has the lowest estimate for diagnosed diabetes among adults (9.2%) and the highest estimate for high blood pressure among adults (31.4%).
| Measure | Kearney | 95% range | Among the 5 Nebraska cities in this research set | Year |
|---|---|---|---|---|
| Obesity among adults | 39.4% | 34.2–44.8% | second-highest | 2023 |
| Diagnosed diabetes among adults | 9.2% | 8–10.5% | lowest | 2023 |
| High blood pressure among adults | 31.4% | 28.3–34.7% | highest | 2023 |
| Lack of health insurance among adults aged 18–64 | 9.6% | 8.3–10.9% | fourth-highest | 2023 |
| Routine checkup in the past year among adults | 74.4% | 71.1–77.6% | fourth-highest | 2023 |
Source: CDC PLACES, 2025 release — model-based estimates from the Behavioral Risk Factor Surveillance System for Census place geography (total population 33,790); each measure is an estimate for adults. These describe the city's adults as a group; they do not indicate whether any person is eligible for, or should use, a treatment listed here.
This tirzepatide page is the Kearney entry point to the Nebraska statewide online listing, not evidence of an office, pharmacy or clinician in Kearney. Each company below appears because its named products have their own Nebraska evidence; the heading does not extend coverage to every medicine in the category, and branded and compounded products are listed separately.
Use the Nebraska guide to compare the listed programs, their separate prices and their billing and cancellation terms before choosing which offer to ask a company about.
These are online services advertised for patients in Nebraska, listed alphabetically. They are not verified offices, pharmacies or clinicians located in Kearney, and a listing is not a prescription, appointment or coverage guarantee. Read the Nebraska Tirzepatide guide for product details, charges and limitations.
Selected providers
Gentle Health
Gentle Health's compounded injectable tirzepatide program, if prescribed, billed through its medication-order subscription.
Compounded injectable tirzepatide (injection): 2.5–5 mg/week — $169/mo · >5–10 mg/week — $219/mo · >10–15 mg/week — $269/mo
- Compounded injectable tirzepatide — injection: state evidence checked · Availability source · Full evidence notes
Official provider website · Product and access details
Medical Director: James Simmons, MD — company-reported; see profile for the source.
GoodRx Care
GoodRx Care Direct's separately priced branded tirzepatide pen, billed apart from its monthly membership fee.
Zepbound KwikPen (pen): introductory KwikPen strength (page labels it 10 mg) — $338/mo
- Zepbound KwikPen — pen: state evidence checked · Availability source · Full evidence notes
More listings
Other medications for Kearney: GLP-1 medication access · Semaglutide
Tirzepatide in other Nebraska cities: Bellevue · Grand Island · Lincoln · Omaha
Before requesting a prescription
Confirm the named product is offered where you will be during the visit, check eligibility, total charges and any supply commitment, and ask what happens if you need in-person care. This listing does not assess which treatment is right for you.